Grupo Vithas, the Healthcare group headed by the Gallardo family and Criteria Caixa bank, has hit trouble in their attempts to buy Valencia based Grupo Hospitales Nisa and its seven healthcare centers throughout Valencia, Madrid and Andalucía provinces. Vithas, based in Madrid and with Catalan backing, has said it intends to complete the takeover in order to widen their network, becoming Spain’s second largest private hospital group.
While Vithas has managed to secure purchasing options from some of Nisa’s major shareholders (totalling around 30% of shares), the company has also met serious resistance from well-organized minority shareholders, who have launched a share-merger process in order to present a united front and “a position of strength.” Together, the resisting shareholders represent over 53% of NIsa’s active shares.
A number of these shareholders have considered Vithas’ move to be a hostile takeover, having rejected their offers and the extended two-year payment plan. As a result, Vithas decided not to press ahead with the initial round of purchases, whose options were to expire in late June.
Full Content: El Confidencial/a>
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hermes Fights Back Against ‘Far-Fetched’ Birkin Bag Lawsuit
May 9, 2024 by
CPI
European Music Streaming Firms Rally Against Apple’s Proposed Remedies
May 9, 2024 by
CPI
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI